Most of the trials in which these patients were enrolled included 1-5 bone sarcoma patients total, with the exceptions of trials that included anti-insulin-like growth factor 1 receptor (IGF-1R) antibodies alone (20 patients) or in combination with mammalian target of rapamycin (mTOR) inhibition (11 patients). This evidence concerns the gene MTOR and bone sarcoma.